Abstract:COVID-19 is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), and according to the World Health Organization (WHO), to date, SARS-CoV-2 has already infected more than 91.8 million people worldwide with 1,986,871 deaths. This virus affects mainly the respiratory system, but the gastrointestinal tract (GIT) is also a target, meanwhile SARS-CoV-2 was already detected in oesophagus, stomach, duodenum, rectum, and in fecal samples from COVID-19 patients. Prolonged GIT manifestations in COVID-19, mainly the diarrhea, were correlated with decreased richness and diversity of the gut microbiota, immune deregulation and delayed SARS-CoV-2 clearance. So, the bidirectional interactions between the respiratory mucosa and the gut microbiota, known as gut-lung axis, are supposed to be involved in the healthy or pathologic immune responses to SARS-CoV-2. In accordance, the intestinal dysbiosis is associated with increased mortality in other respiratory infections, due to an exacerbated inflammation and decreased regulatory or anti-inflammatory mechanisms in the lungs and in the gut, pointing to this important relationship between both mucosal compartments. Therefore, since the mucous membranes from the respiratory and gastrointestinal tracts are affected, in addition to dysbiosis and inflammation, it is plausible to assume that adjunctive therapies based on the modulation of the gut microbiota and re-establishment of eubiosis conditions could be an important therapeutic approach for constraining the harmful consequences of COVID-19. Then, in this review, we summarized studies showing the persistence of SARS-CoV-2 in the gastrointestinal system and the related digestive COVID-19 manifestations, in addition to the literature demonstrating nasopharyngeal, pulmonary and intestinal dysbiosis in COVID-19 patients. Lastly, we showed the potential beneficial role of probiotic administration in other respiratory infections, and discuss the possible role of probiotics as an adjunctive therapy in SARS-CoV-2 infection.

The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes

Microbial and Immune Regulation of the Gut-Lung Axis during Viral-Bacterial Coinfection

Microbiota Modulation of the Gut-Lung Axis in COVID-19

The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections

Lung and Gut Affair

The lung-gut axis and COVID-19

Roles of the gut microbiota in severe SARS-CoV-2 infection

From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis

Gut-lung axis and dysbiosis in COVID-19

The Gut-Lung Axis in Respiratory Disease

A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases

Gut Microbiome and COVID 19 Role of Probiotics on Gut Lung Axis

The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks

Gut-Lung Axis-A Compass to Navigate Microbiome Landscape in COVID-19

Impact of SARS-CoV2 infection on gut microbiota dysbiosis

Role of the intestinal microbiota in host defense against respiratory viral infections

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Gut microbiota: A new insight into lung diseases

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

Impact of SARS-CoV-2 infection on respiratory and gut microbiome stability: a metagenomic investigation in long-term-hospitalized COVID-19 patients

Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections